ASCO GI Cancers Symposium - American Society of Clinical Oncology Gastrointestinal Cancers Symposium

Compared to embolization alone, the systemic treatment combination nearly doubled progression-free survival among patients with unresectable liver cancer.

Radioligands may be able to deliver radiation to advanced tumor cells anywhere in the body.

Compared to TACE alone, durvalumab plus TACE and bevacizumab reduced the risk of disease progression or death by 23%; however, further research is needed to assess OS.

Compared with chemotherapy, nivolumab plus ipilimumab reduced the risk of disease progression or death by 79%, but further research is needed to assess overall survival.

Zolbetuximab treatment reduced risk of death by 25% compared to placebo.

Data from the FIGHT trial suggests that approximately 30% of patients with non-human epidermal growth factor 2-positive GEJ cancers overexpress fibroblast growth factor receptor 2.

The efficacy results demonstrated that there were 4 patients with confirmed partial response, and an additional 3 patients had stable disease lasting 16 weeks or longer.

Data from a phase 1b/2 trial investigating the treatment of CCA with the combination of silmitasertib plus gemcitabine and cisplatin in comparison with gemcitabine and cisplatin found a statistically significant difference.

The treatment of 5-fluorouracil with levofolinate and irinotecan was found to be well-tolerated and effective as a second-line treatment for patients with gemcitabine-refractory advanced pancreatic cancer.

Data from a phase 1b/2 study investigating onvansertib as a treatment of KRAS-mutated mCRC demonstrated that 42% of patients achieved a PR and 67% demonstrated a durable response ranging from 6.1 months to 13.7 months.

According to Senhwa Biosciences, the study’s findings indicate a clinically meaningful improvement in progression-free survival (PFS) (P